Please assess the completion status of the following clinical trial:

Trial Title: Influenza HA Ferritin Vaccine, Alone or in Prime-Boost Regimens With an Influenza DNA Vaccine in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
INCLUSION CRITERIA:~A subject must meet all of the following criteria:~* Healthy subjects aged 18-70 (excluding subjects born between 1966-1969)~* Based on history and examination, must be in good general health and without history of any of the conditions listed in the exclusion criteria~* Received at least one licensed current seasonal influenza vaccine from 2014 to the present~* Able and willing to complete the informed consent process~* Available for clinic visits for 40 weeks after enrollment~* Willing to have blood samples collected, stored indefinitely, and used for research purposes~* Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process~* Physical examination and laboratory results without clinically significant findings and a Body Mass Index (BMI) less than or equal to 40 within the 84 days before enrollment~Laboratory Criteria within 84 days before enrollment:~* White blood cells (WBC) and differential either within institutional normal range or accompanied by the site Principal Investigator (PI) or designee approval~* Total lymphocyte count greater than or equal to 800 cells/mm\^3~* Platelets = 125,000 - 500,000/mm\^3~* Hemoglobin within institutional normal range~* Serum iron either within institutional normal range or accompanied by the site PI or designee approval~* Alanine aminotransferase (ALT) less than or equal to 1.25 times institutional upper limit of normal (ULN)~* Aspartate aminotransferase (AST) less than or equal to 1.25 times institutional ULN~* Alkaline phosphatase (ALP) less than or equal to 1.1 times institutional ULN~* Total bilirubin within institutional ULN~* Serum creatinine less than or equal to 1.1 times institutional ULN~* Negative for HIV infection by an FDA approved method of detection~Criteria applicable to women of childbearing potential:~* Negative beta-human chorionic gonadotropin (Beta-HCG) pregnancy test (urine or serum) on the day of enrollment~* Agrees to use an effective means of birth control from at least 21 days prior to enrollment through the end of the study~EXCLUSION CRITERIA:~A subject will be excluded if one or more of the following conditions apply:~- Breast-feeding or planning to become pregnant during the study.~Subject has received any of the following substances:~* More than 10 days of systemic immunosuppressive medications or cytotoxic medications within the 4 weeks prior to enrollment or any within the 14 days prior to enrollment~* Blood products within 16 weeks prior to enrollment~* Live attenuated vaccines within 4 weeks prior to enrollment~* Inactivated vaccines within 2 weeks prior to enrollment.~* Investigational research agents within 4 weeks prior to enrollment or planning to receive investigational products while on the study~* Current allergy treatment with allergen immunotherapy with antigen injections, unless on maintenance schedule~* Current anti-tuberculosis (TB) prophylaxis or therapy~* Previous H2 influenza investigational vaccine~* Receipt of a licensed influenza vaccine within 6 weeks before trial enrollment~Subject has a history of any of the following clinically significant conditions:~* Serious reactions to vaccines that preclude receipt of study vaccinations as determined by the investigator~* Hereditary angioedema, acquired angioedema, or idiopathic forms of angioedema~* Asthma that is not well controlled~* Diabetes mellitus (type I or II), with the exception of gestational diabetes~* Thyroid disease that is not well controlled~* Idiopathic urticaria within the past year~* Evidence of autoimmune disease or immunodeficiency~* Hypertension that is not well controlled~* Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws~* Malignancy that is active or history of malignancy that is likely to recur during the period of the study.~* Seizure disorder other than 1) febrile seizures, 2) seizures secondary to alcohol withdrawal more than 3 years ago, or 3) seizures that have not required treatment within the last 3 years~* Asplenia, functional asplenia or any condition resulting in the absence or removal of the spleen~* Guillain-Barre Syndrome~* Psychiatric condition that precludes compliance with the protocol; past or present psychoses; or within 5 years prior to enrollment, a history of suicide plan or attempt~* Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a subject's ability to give informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Group 1: HA-F A/Sing (20 mcg), ages 18-47 Yrs (Type: EXPERIMENTAL): HA-F A/Sing injections (20 mcg) administered intramuscularly (IM) by Needle/Syringe (Day 0) in H2-naïve adults (adults with no pre-existing immunity to H2)
- Group 2: HA-F A/Sing (60 mcg), ages 18-47 Yrs (Type: EXPERIMENTAL): HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16) in H2-naïve adults (adults with no pre-existing immunity to H2)
- Group 3A: DNA A/Sing(4 mg)-HA-F A/Sing(60 mcg), ages 18-47 Yrs (Type: EXPERIMENTAL): DNA A/Sing injections (4 mg) administered IM by PharmaJet (Day 0); HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Week 16) in H2-naïve adults (adults with no pre-existing immunity to H2)
- Group 3B: DNA A/Sing(4 mg)-HA-F A/Sing(60 mcg), ages 52-70 Yrs (Type: EXPERIMENTAL): DNA A/Sing injections (4 mg) administered IM by PharmaJet (Day 0); HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Week 16) in H2-exposed adults (may have some H2 immunity)
- Group 4A: HA-F A/Sing (60 mcg), ages 18-47 Yrs (Type: EXPERIMENTAL): HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16) in H2-naïve adults (adults with no pre-existing immunity to H2)
- Group 4B: HA-F A/Sing (60 mcg), ages 52-70 Yrs (Type: EXPERIMENTAL): HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16) in H2-exposed adults (may have some H2 immunity)

Based on this trial design, predict the completion outcome and termination type (if applicable).